MedWatch

CEO: Zealand is changing

In 2011 the Danish company Zealand Pharma was a profitable business and it expects to be so in 2012 as well. “We are actually doing business in the next generation of the biotech world,” the company CEO says. He also explains the basis of the company’s growing research costs.

Foto: Niels Hougaard / Jyllands-Posten

With promising news and increased expectations Zealand Pharma has once again shown its success to investors. It indicates that the biotech company is entering a significant stage in its maturity, says CEO David Solomon.

“The interesting part is that we guided for profitability in 2012, and we were profitable in 2011. Two years in a row we set the bar for a maturing biotech company like Zealand. We are actually doing business in the next generation of the biotech world,” David Solomon tells Medwatch.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier